spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  DNA Damage Response 

 HSMN NewsFeed - 16 Feb 2024
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 2 Jan 2023
Blacksmith Medicines Announces Merger with Forge Therapeutics to Create Leading Company Developing Medicines Targeting Metalloenzymes
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Feb 2021
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Dec 2020
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2020
Vividion Therapeutics Appoints Drug Discovery and Development Expert, Robert Abraham, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2019
Artios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2019
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Apr 2019
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2018
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2008
ArQule Announces Appointment of Brian Schwartz as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2008
Stephen Hill, ArQule President and CEO, to Join Solvay Pharmaceuticals, Inc. as New President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2008
ArQule Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2007
ArQule Names Peter Lawrence Chief Operating Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
DNA Damage Response
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.